Soligenix publishes Phase 2a study results for SGX945 in Behçet's Disease treatment.
ByAinvest
Thursday, Dec 18, 2025 7:42 am ET1min read
SNGX--
Soligenix has published the results of a Phase 2a study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease. The study showed beneficial effects for 7 of 8 patients and a potentially enduring effect through 4 weeks of follow-up. SGX945 is a peptide inhibitor of IL-1α and IL-1β that has shown promise in treating this difficult-to-treat orphan disease.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet